• Contact us: 01476 247 007
    Pharmacovigilance (QPPV) provision post-BrexitPharmacovigilance (QPPV) provision post-BrexitPharmacovigilance (QPPV) provision post-BrexitPharmacovigilance (QPPV) provision post-Brexit
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    Is your pharmaceutical company Brexit ready?
    15th January 2020
    What happens after Brexit for Pharmacovigilance and Regulatory?
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    Pharmacovigilance (QPPV) provision post-Brexit

    7th February 2020
    Pharmacovigilance (QPPV) provision post-Brexit

    Pharmacovigilance (QPPV) provision post-BrexitThere has been and still is a huge amount of confusion regarding the requirements for establishing a UK QPPV following the UK’s exit from Europe on 31st January 2020, creating challenges for pharmaceutical companies.

    Pure Drug Safety is here to help you with what we know so far about QPPV provision post-Brexit:

    Pharmacovigilance (QPPV)

    If your current EU/EEA QPPV resides within an EU state then there is a temporary exemption in place, which allows 21 months beginning from exit day to allow you to appoint a UK QPPV that resides and operates in the UK.

    However, if your current QPPV is UK based, then after  31st December 2020, they  will not be able to act as a EU QPPV.

    In the midst of this confusion, you can rely on Pure Drug Safety to help you make the transitions you need to enable you to carry out your QPPV tasks in the EU/EEA.

    PDS already has a highly qualified and experienced team based in Europe who can be your:

    • EU QPPV for Pharmacovigilance
    • Deputy QPPV for Pharmacovigilance
    • Responsible Person for Eudravigilance in clinical trials

    Call us now on +44(0) 1476 512395 to discuss your Pharmacovigilance (QPPV) provision post-Brexit with one of our team.

    Share

    Related posts

    MHRA post-transition period information from Pure Drug Safety
    23rd October 2020

    MHRA and EMA latest guidance on Brexit


    Read more
    MHRA post-transition period information from Pure Drug Safety
    3rd September 2020

    MHRA post-transition period information


    Read more
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    What happens after Brexit for Pharmacovigilance and Regulatory?


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA